Dexmedetomidine: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Dexmedetomidine. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Hypotension requiring intervention | 28% |
| Hypotension | 25% |
| Hypertension | 19% |
| Hypokalemia | 13% |
| Nausea | 11% |
| Tachycardia requiring intervention | 10% |
| Anxiety | 9% |
| Atrial fibrillation | 7% |
| Hypomagnesemia | 7% |
| Atelectasis | 6% |
| Pleural effusion | 6% |
| Constipation | 6% |
| Hypoglycemia | 6% |
| Generalized edema | 6% |
| Bradycardia | 5% |
| Vomiting | 5% |
| Hypovolemia | 5% |
| Ventricular tachycardia | 5% |
| Fever | 5% |
| Bradycardia requiring intervention | 5% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
1.1 Intensive Care Unit Sedation Dexmedetomidine injection is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Dexmedetomidine injection should be administered by continuous infusion not to exceed 24 hours. Dexmedetomidine injection has been continuously infused in mechanically ventilated adult patients prior to extubation, during extubation, and post-extubation. It is not necessary to discontinue dexmedetomidine injection prior to extubation. 1.2 Procedural Sedation Dexmedetomidine injection is indicated for sedation of non-intubated adult patients prior to and/or during surgical and other procedures. Pediatric use information is approved for Hospira Inc.’s PRECEDEXTM (dexmedetomidine hydrochloride) injection. However, due to Hospira Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.